Search Results

The global pandemic has exposed serious flaws in supply chains, including critical ones for industries such as pharma and medical supplies. Shortages of personal protective equipment for health workers and ventilators in hospitals are the most prominent ones. To prevent this problem from occurring again when the next disaster strikes, governments should consider establishing a stress test for companies that provide critical goods and services that’s akin to the stress tests for banks that the U.S. government and European Union instituted after the 2008 financial crisis. This test should focus on the resilience of companies’ supply chains.

The pharmaceutical industry has experienced an extraordinary rise in the generation and use of enormous datasets. Nevertheless, there remain great challenges on this front regarding everything from target identification to understanding the performance of marketed products. In the context of this broad impact, we have assembled a group of leading researchers and executives from the MIT-connected community who will address questions of discovery, data integration, and system perturbation analysis, including use of artificial intelligence and machine learning techniques. What is the impact of current developments on high-throughput profiling, computational biology, and validation of gene targets? How do these developments impact the use of chemical libraries, drug-delivery systems, and patient-facing objectives? These are the types of questions that will be addressed in this exciting panel discussion.

Transistor footprint scaling is rapidly approaching its limits. But this is not about to slow the rapid progress of information processing technology. On the contrary, 3D integration involving new material systems and devices opens a new era with unprecedented promise.